Celgosivir hydrochloride is an α-glucosidase I inhibitor with potent antiviral activity against HIV-1 (IC50 = 2.0 ± 2.3 μM), bovine viral diarrhea virus (BVDV; IC50 = 16 μM in plaque assay and 47 μM in cytopathic effect assay), and dengue virus serotypes 1–4 (EC50 ≤ 0.7 μM, with EC50 = 0.2 μM for DENV2). It effectively protects AG129 mice from lethal dengue virus infection when administered at 50 mg/kg twice daily for 5 days, even with treatment delayed up to 48 hours post-infection.